179 related articles for article (PubMed ID: 9034372)
1. Amplification and overexpression of MDM2 in primary (de novo) glioblastomas.
Biernat W; Kleihues P; Yonekawa Y; Ohgaki H
J Neuropathol Exp Neurol; 1997 Feb; 56(2):180-5. PubMed ID: 9034372
[TBL] [Abstract][Full Text] [Related]
2. Glioblastoma multiforme in an Asian population: evidence for a distinct genetic pathway.
Das A; Tan WL; Teo J; Smith DR
J Neurooncol; 2002 Nov; 60(2):117-25. PubMed ID: 12635658
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas.
Watanabe K; Tachibana O; Sata K; Yonekawa Y; Kleihues P; Ohgaki H
Brain Pathol; 1996 Jul; 6(3):217-23; discussion 23-4. PubMed ID: 8864278
[TBL] [Abstract][Full Text] [Related]
4. Necrogenesis and Fas/APO-1 (CD95) expression in primary (de novo) and secondary glioblastomas.
Tohma Y; Gratas C; Van Meir EG; Desbaillets I; Tenan M; Tachibana O; Kleihues P; Ohgaki H
J Neuropathol Exp Neurol; 1998 Mar; 57(3):239-45. PubMed ID: 9600216
[TBL] [Abstract][Full Text] [Related]
5. Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas.
Biernat W; Tohma Y; Yonekawa Y; Kleihues P; Ohgaki H
Acta Neuropathol; 1997 Oct; 94(4):303-9. PubMed ID: 9341929
[TBL] [Abstract][Full Text] [Related]
6. p53 mutations versus EGF receptor expression in giant cell glioblastomas.
Peraud A; Watanabe K; Plate KH; Yonekawa Y; Kleihues P; Ohgaki H
J Neuropathol Exp Neurol; 1997 Nov; 56(11):1236-41. PubMed ID: 9370234
[TBL] [Abstract][Full Text] [Related]
7. Genetic profile of gliosarcomas.
Reis RM; Könü-Lebleblicioglu D; Lopes JM; Kleihues P; Ohgaki H
Am J Pathol; 2000 Feb; 156(2):425-32. PubMed ID: 10666371
[TBL] [Abstract][Full Text] [Related]
8. Analysis of mdm2 and p53 gene alterations in glioblastomas and its correlation with clinical factors.
Schiebe M; Ohneseit P; Hoffmann W; Meyermann R; Rodemann HP; Bamberg M
J Neurooncol; 2000 Sep; 49(3):197-203. PubMed ID: 11212898
[TBL] [Abstract][Full Text] [Related]
9. Primary and secondary glioblastomas: from concept to clinical diagnosis.
Kleihues P; Ohgaki H
Neuro Oncol; 1999 Jan; 1(1):44-51. PubMed ID: 11550301
[TBL] [Abstract][Full Text] [Related]
10. Primary glioblastomas with and without EGFR amplification: relationship to genetic alterations and clinicopathological features.
Benito R; Gil-Benso R; Quilis V; Perez M; Gregori-Romero M; Roldan P; Gonzalez-Darder J; Cerdá-Nicolas M; Lopez-Gines C
Neuropathology; 2010 Aug; 30(4):392-400. PubMed ID: 20051017
[TBL] [Abstract][Full Text] [Related]
11. p53 mutation and epidermal growth factor receptor overexpression in glioblastoma.
Yoon KS; Lee MC; Kang SS; Kim JH; Jung S; Kim YJ; Lee JH; Ahn KY; Lee JS; Cheon JY
J Korean Med Sci; 2001 Aug; 16(4):481-8. PubMed ID: 11511795
[TBL] [Abstract][Full Text] [Related]
12. A comparative study of epidermal growth factor receptor (EGFR) and MDM2 gene amplification and protein immunoreactivity in human glioblastomas.
Rieske P; Kordek R; Bartkowiak J; Debiec-Rychter M; Biernat W; Liberski PP
Pol J Pathol; 1998; 49(3):145-9. PubMed ID: 9810172
[TBL] [Abstract][Full Text] [Related]
13. PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas.
Tohma Y; Gratas C; Biernat W; Peraud A; Fukuda M; Yonekawa Y; Kleihues P; Ohgaki H
J Neuropathol Exp Neurol; 1998 Jul; 57(7):684-9. PubMed ID: 9690672
[TBL] [Abstract][Full Text] [Related]
14. Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors.
Burton EC; Lamborn KR; Forsyth P; Scott J; O'Campo J; Uyehara-Lock J; Prados M; Berger M; Passe S; Uhm J; O'Neill BP; Jenkins RB; Aldape KD
Clin Cancer Res; 2002 Jan; 8(1):180-7. PubMed ID: 11801556
[TBL] [Abstract][Full Text] [Related]
15. Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas.
Sung T; Miller DC; Hayes RL; Alonso M; Yee H; Newcomb EW
Brain Pathol; 2000 Apr; 10(2):249-59. PubMed ID: 10764044
[TBL] [Abstract][Full Text] [Related]
16. Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities.
Ichimura K; Bolin MB; Goike HM; Schmidt EE; Moshref A; Collins VP
Cancer Res; 2000 Jan; 60(2):417-24. PubMed ID: 10667596
[TBL] [Abstract][Full Text] [Related]
17. Refined mapping of 12q13-q15 amplicons in human malignant gliomas suggests CDK4/SAS and MDM2 as independent amplification targets.
Reifenberger G; Ichimura K; Reifenberger J; Elkahloun AG; Meltzer PS; Collins VP
Cancer Res; 1996 Nov; 56(22):5141-5. PubMed ID: 8912848
[TBL] [Abstract][Full Text] [Related]
18. Analysis of glioma cell lines for amplification and overexpression of MDM2.
He J; Reifenberger G; Liu L; Collins VP; James CD
Genes Chromosomes Cancer; 1994 Oct; 11(2):91-6. PubMed ID: 7529554
[TBL] [Abstract][Full Text] [Related]
19. Deregulation of the p14ARF/Mdm2/p53 pathway and G1/S transition in two glioblastoma sets.
Ghimenti C; Fiano V; Chiadò-Piat L; Chiò A; Cavalla P; Schiffer D
J Neurooncol; 2003 Jan; 61(2):95-102. PubMed ID: 12622447
[TBL] [Abstract][Full Text] [Related]
20. Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes.
Newcomb EW; Cohen H; Lee SR; Bhalla SK; Bloom J; Hayes RL; Miller DC
Brain Pathol; 1998 Oct; 8(4):655-67. PubMed ID: 9804374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
